Hospital Pharmacy welcomes contributions to this column. Articles originally published in pharmacy department newsletters are reprinted here. Material is selected because of its educational value to pharmacists or because it demonstrates the type of information of interest to newsletter readers. If you wish to have your newsletter material considered for publication in this column, mail a copy—along with a computer disk containing the document—to Neil M. Davis, Editor-in-Chief, Hospital Pharmacy, 1143 Wright Drive, Huntingdon Valley, PA 19006-2721.
Get full access to this article
View all access options for this article.
References
1.
GuptaS., CammA.J.Chronic infection in the etiology of atherosclerosis: The case for chlamydia pneumoniae. Clin Cardiol.1997; 20: 829–36.
ThomD.H., GraystonJ T., SiscovickD.S.Association of prior infection with chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA.1992; 268: 68–72.
4.
SaikkuP., LeinonenM., TenkanenL.Chronic chlamydia pneumoniae infection as a risk factor for coronary heart disease in the helsinki heart study. Ann Intern Med.1992; 116: 273–8.
5.
RidkerP.M., KundsinR.B., StampferM.J.Prospective study of chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation.1999; 99: 1161–4.
6.
KuoC., ShorA.Demonstration of chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis.1993; 167: 841–9.
7.
RamirezJ.A.Isolation of chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Ann Intern Med.1996; 125: 979–82.
8.
LibbyP., EganD., SkarlatosS.Roles of infectious agents in atherosclerosis and restenosis. Circulation.1997; 96: 4095–4103.
9.
NollG.Pathogenesis of atherosclerosis: A possible relation to infection. Atherosclerosis.1998; 140(suppl 1): S3–9.
10.
GurfinkelE., BozovichG.Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet.1997; 350: 404–7.
11.
GurfinkelE., BozovichG., BeckE.Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. Eur Heart J.1999; 20: 121–7.
12.
GuptaS., LeathamE.W., CarringtonD.Elevated chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation.1997; 96(2): 404–7.
13.
AndersonJ.L., MuhlesteinJ.B., CarlquistJ.Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for chlamydia pneumoniae infection. Circulation.1999; 99: 1540–7.
14.
MeierC.R., DerbyL.E., JickS.S.Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA.1999; 281: 427–31.
15.
GraystonJ T.Antibiotic treatment trials for secondary prevention of coronary artery disease events. Circulation.1999; 99: 1538–9.
